These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 30392300)

  • 1. [Pancreatic cancer with liver metastases: is it possible to improve survival by resection of oligopersistent primary tumor following neoadjuvant chemotherapy?].
    Kelemen D; Mangel L; Szabó Z; Varga Á; Palkovics A; Vereczkei A
    Orv Hetil; 2023 Oct; 164(43):1712-1718. PubMed ID: 37898915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A commentary on 'The experience of neoadjuvant chemotherapy versus upfront surgery in resectable pancreatic cancer: a cross sectional study'.
    Chen Y; Wang C; Zhao Y
    Int J Surg; 2023 Oct; 109(10):3209-3210. PubMed ID: 37402310
    [No Abstract]   [Full Text] [Related]  

  • 3. Neoadjuvant treatment for pancreatic cancer: Controversies and advances.
    Dias E Silva D; Chung V
    Cancer Treat Res Commun; 2024; 39():100804. PubMed ID: 38508132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiochemotherapy in Pancreatic Cancer.
    Domagała-Haduch M; Gorzelak-Magiera A; Michalecki Ł; Gisterek-Grocholska I
    Curr Oncol; 2024 Jun; 31(6):3291-3300. PubMed ID: 38920733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Female advantage in neoadjuvant pancreatic cancer therapy: is it down to macrophages?
    Michl P; Roth L
    Gut; 2024 Jan; 73(2):214-215. PubMed ID: 37813566
    [No Abstract]   [Full Text] [Related]  

  • 6. Letter to the editor: Understanding surgical attrition for "resectable" pancreatic cancer.
    Brown ZJ; Cloyd JM
    HPB (Oxford); 2024 Apr; 26(4):606-607. PubMed ID: 38246826
    [No Abstract]   [Full Text] [Related]  

  • 7. A commentary on 'The experience of neoadjuvant chemotherapy versus upfront surgery in resectable pancreatic cancer. A cross sectional study' - a correspondence.
    Li XL; Liu ZP; Dai HS; Yin XY; Chen ZY
    Int J Surg; 2023 Dec; 109(12):4347-4348. PubMed ID: 38259003
    [No Abstract]   [Full Text] [Related]  

  • 8. Neoadjuvant Therapy in Borderline Resectable Pancreatic Cancer.
    Barreto SG; Shrikhande SV; Sirohi B
    Indian J Surg Oncol; 2024 May; 15(Suppl 2):249-254. PubMed ID: 38817993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The timing and design of stereotactic radiotherapy approaches as a part of neoadjuvant therapy in pancreatic cancer: Is it time for change?
    Ryckman JM; Reames BN; Klute KA; Hall WA; Baine MJ; Abdel-Wahab M; Lin C
    Clin Transl Radiat Oncol; 2021 May; 28():124-128. PubMed ID: 33981865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ESMO 2023 pancreatic cancer guidelines signal stepwise progress.
    Springfeld C; Bailey P; Büchler MW; Neoptolemos JP
    Hepatobiliary Surg Nutr; 2024 Apr; 13(2):362-365. PubMed ID: 38617485
    [No Abstract]   [Full Text] [Related]  

  • 11. ALLIANCE A021806: A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer.
    Eade AV; Friedman LR; Larrain C; Rainey A; Hernandez JM; Chawla A; Ferrone CR
    Ann Surg Oncol; 2024 Jul; ():. PubMed ID: 39048905
    [No Abstract]   [Full Text] [Related]  

  • 12. Prognostic impact of tumor marker kinetics and normalization during neoadjuvant chemotherapy for pancreatic cancer.
    Hayashi H; Liu Z; Sun Y; Ogawa D; Baba H
    Hepatobiliary Surg Nutr; 2024 Apr; 13(2):317-320. PubMed ID: 38617470
    [No Abstract]   [Full Text] [Related]  

  • 13. A commentary on "Metabolic tumor burden as a prognostic indicator after neoadjuvant chemotherapy in pancreatic cancer".
    Wang C; Li Y; Tian B
    Int J Surg; 2024 May; ():. PubMed ID: 38716870
    [No Abstract]   [Full Text] [Related]  

  • 14. Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05).
    Motoi F; Kosuge T; Ueno H; Yamaue H; Satoi S; Sho M; Honda G; Matsumoto I; Wada K; Furuse J; Matsuyama Y; Unno M;
    Jpn J Clin Oncol; 2019 Feb; 49(2):190-194. PubMed ID: 30608598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Hope and frustration of neoadjuvant chemotherapy for resectable pancreatic cancer].
    Lu C; Miao Y; Gao WT
    Zhonghua Wai Ke Za Zhi; 2018 Nov; 56(11):813-816. PubMed ID: 30392300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival.
    Rose JB; Rocha FG; Alseidi A; Biehl T; Moonka R; Ryan JA; Lin B; Picozzi V; Helton S
    Ann Surg Oncol; 2014 May; 21(5):1530-7. PubMed ID: 24473642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Neoadjuvant treatment of primarily resectable and borderline resectable pancreatic cancer].
    Scheufele F; Friess H
    Chirurg; 2020 May; 91(5):391-395. PubMed ID: 31965198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant chemotherapy versus surgery first for resectable pancreatic cancer (Norwegian Pancreatic Cancer Trial - 1 (NorPACT-1)) - study protocol for a national multicentre randomized controlled trial.
    Labori KJ; Lassen K; Hoem D; Grønbech JE; Søreide JA; Mortensen K; Smaaland R; Sorbye H; Verbeke C; Dueland S
    BMC Surg; 2017 Aug; 17(1):94. PubMed ID: 28841916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resection of Borderline Resectable and Locally Advanced Pancreatic Adenocarcinomas after Neoadjuvant Chemotherapy.
    Addeo P; Rosso E; Fuchshuber P; Oussoultzoglou E; De Blasi V; Simone G; Belletier C; Dufour P; Bachellier P
    Oncology; 2015; 89(1):37-46. PubMed ID: 25766660
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.